NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD

[1]  M. Tremelling,et al.  HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants , 2014, Nature Genetics.

[2]  B. Ye,et al.  ATG16L1 contributes to Crohn's disease susceptibility in Koreans: overmuch concern for ethnic difference? , 2014, Gut.

[3]  Jianjun Liu,et al.  A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia , 2014, Nature Genetics.

[4]  J. Andrews,et al.  PACSIN2 Does Not Influence Thiopurine-Related Toxicity In Patients With Inflammatory Bowel Disease , 2014, The American Journal of Gastroenterology.

[5]  T. Komiyama,et al.  Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients , 2014, Leukemia & lymphoma.

[6]  Y. Mazor,et al.  Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease. , 2013, Current drug safety.

[7]  J. Mate,et al.  Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients , 2013, Inflammatory bowel diseases.

[8]  Yusuke Nakamura,et al.  Association Study of 71 European Crohn's Disease Susceptibility Loci in a Japanese Population , 2013, Inflammatory bowel diseases.

[9]  M. Relling,et al.  PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. , 2012, Human molecular genetics.

[10]  Y. Yamagata,et al.  Human MTH3 (NUDT18) Protein Hydrolyzes Oxidized Forms of Guanosine and Deoxyguanosine Diphosphates , 2012, The Journal of Biological Chemistry.

[11]  J. Lo-Guidice,et al.  Evidence for a functional genetic polymorphism of the Rho-Gtpase Rac1: Implication in azathioprine response? , 2011 .

[12]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[13]  K. Yao,et al.  Adverse reactions to azathioprine cannot be predicted by thiopurine S‐methyltransferase genotype in Japanese patients with inflammatory bowel disease , 2009, Journal of gastroenterology and hepatology.

[14]  A. Andoh,et al.  Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease. , 2008, Internal medicine.

[15]  Yusuke Nakamura,et al.  Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients , 2007, Journal of Human Genetics.

[16]  R. Gearry,et al.  Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease , 2004, Pharmacoepidemiology and drug safety.

[17]  T. Hibi,et al.  Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis , 2003, Journal of Gastroenterology.

[18]  D. Jewell,et al.  The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review , 2002, Gut.

[19]  B. Bonaz,et al.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.

[20]  M. Barnardo,et al.  Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). , 1995, Tissue antigens.

[21]  D. Jewell,et al.  Azathioprine in Ulcerative Colitis: Final Report on Controlled Therapeutic Trial , 1974, British medical journal.

[22]  G. Keele.  Letter: Rubella vaccination. , 1973, Lancet.

[23]  D. Bainton,et al.  Controlled trial of azathioprine in Crohn's disease. , 1971, Lancet.

[24]  A. Dawson,et al.  Controlled trial of azathioprine in Crohn's disease. , 1971, Lancet.